Arlington Partners’s Bio-Techne TECH Stock Holding History

Arlington Partners’s Portfolio TECH Stock Details TECH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-130	Closed	-$10.6K	–	574
2023 Q2	$10.6K	Buy	+130	New	+$10.4K	﹤0.01%	460

Other funds holding TECH

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BAMCO Inc New York $33.1B AUM 11.16% 1-Year Est. Return

Select Equity Group New York $19.5B AUM 17.33% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

DDC

DF Dent & Co Baltimore, Maryland $5.22B AUM 2.07% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Arlington Partners's TECH Position: Q3 2023 in Review

Arlington Partners sold out of Bio-Techne (TECH) in Q3 2023, closing a stake of 130 shares — an estimated $10.6K sold.

Arlington Partners first reported a position in TECH in Q2 2023 and held it in 1 quarter. The position peaked at $10.6K in Q2 2023. 529 funds tracked by Wall St. Rank hold TECH as of Q3 2023.

Arlington Partners reported no remaining Bio-Techne position as of Q3 2023 after selling out during the quarter.
Arlington Partners sold 130 Bio-Techne shares in Q3 2023, an estimated $10.6K.
Arlington Partners first reported a position in Bio-Techne in Q2 2023 and held it in 1 quarter.
Arlington Partners's Bio-Techne position peaked at $10.6K in Q2 2023.
529 funds tracked by Wall St. Rank held Bio-Techne as of Q3 2023.

Based on Arlington Partners's 13F filing for Q3 2023, filed 24 Oct 2023.